Another study conducted by Pavicic et al. demonstrated the synergistic effect of combining IL-12-based immunotherapy with dual PD-1/CTLA4 inhibition in a preclinical ovarian cancer mouse model [42]. Here, CTLA4 is linked to ovarian cancer.